CClinicalTrials.gg
Status unknownNCT02480179Updated Jun 24, 2015

CNS Modification of Food Craving by Neurofeedback

An interventional study of H.E.G. (hematoencephalography) based neurofeedback in Obesity, sponsored by Sheba Medical Center. Status unknown. Open to male participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-24.

Sponsored by Sheba Medical Center · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2015), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
20 Years to 50 Years
Sex
Male
01

Study summary

The investigators plan to evaluate H.E.G. (Hematoencephalography) modality in brain modulation of appetite and food craving in a randomized controlled study. The H.E.G. will serve as the neurofeedback modality while the functional brain imaging will enable assessment and hopefully validation of changes brain activity related to food craving and self-control. H.E.G. is a relatively new neurofeedback technique which similar to fMRI, is based on changes in blood oxygenation level as a result of regional brain activation. The unique advantage of this technology regarding our enterprise is that it inheritably samples the two brain areas that are in our focus of interest: the superior orbito-frontal cortex (OFC) which Involved in self-control and reward processing, and the anterior cingulate cortex (ACC) which processes cognitive and emotional information. The investigators will combine HRV (Heart rate variability) biofeedback, which is a well-established treatment form in the investigators therapeutic sessions and will correlate functional neuroimaging with behavioral, anthropometric and laboratory data.

The intervention name is: Measurements of blood flow changes within the brain and online visual feedback to the participant by a H.E.R. (Hematoencephalography) N.I,R (Near Infra Red sensor) sensor made by MindMedia, The Netherlands and a NEXUX4 Hardware, Bluetooth unit, Bio Trace Plus software made by MindMedia, The Netherlands.

Hypothesis: The neurofeedback practice sessions are expected to facilitate improved control of blood flow to frontal brain areas, as a marker of brain activity in these areas

Read the detailed description

CNS Modification of Food Craving by Neurofeedback Study Protocol Research Plan and Methodology

The investigators's goal is to modulate food craving and eating behavior among overweight and obese participants using and interventional neurofeedback program. During the study period, each participant will go through 10 neurofeedback sessions, two sessions per week, over a five-week period. In addition, each participant will go through two functional MRI sessions, the first session, before the neurofeedback intervention, to document baseline neurocognitive response to food stimuli using a specified paradigm and the second - after completion of the neurofeedback series, in order to evaluate changes in C.N.S. response to food.

Subjects: 6 overweight and obese participants will be participate in our pilot study and will go through 2 fMRI sessions, 10 H.E.G. sessions and 3 anthropometric and metabolic evaluations during one year intervention and follow-up.

Study Design: In the investigators's single arm pilot study participants will go through a series of neurofeedback sessions with psychological, anthropomorphic, and laboratory evaluation taken before and after intervention.

Baseline questioners: Baseline assessment will include completion of a combined questionnaire that will address a spectrum eating behavior traits, including hunger and craving, addiction, impulsivity, binge eating, addiction, impulsivity, hedonic eating and externally driven eating14-23.

Anthropomorphic measurements: Height, weight, waist circumference and BMI will be measured before intervention. Weight and calculated BMI will be documented twice more: at week 7-8, soon after accomplishing the Neurofeedback sessions series and at week 12.

The investigators intend to call participants 6 and 12 months after study start and ask for their current weight.

Blood samples: Gut peptides and hormones that are known to parallel weight changes will be measured in the first and last visits including: leptin, morning cortisol, TSH, Ft4 and TT3. In addition, before each fMRI session we will evaluate "satiety profile" by documenting levels of Ghrelin, PYY, c-peptide and insulin.

Functional MRI sessions Experimental Paradigm Based on current knowledge regarding brain areas involved in food craving, the investigators defined two ROIs (regions of interest) that correspond with the introspective tasks in the H.E.G. neurofeedback sessions, one area in the superior orbitofrontal cortex (sOFC.) bilaterally and the second: the anterior cingulated cortex (ACC) bilaterally. Each ROI will be mapped in a block design paradigm (7:22 min) in which visual food stimuli will be shown alternately with neutral visual stimuli (neutral objects) and fixation (8 cycles, 54sec each including 3 blocks, 18s each of fixation, neutral objects, and food stimuli).

For the investigator's specific modulation goal, the suitable in-scanner satiety status is "half satiated". On one hand, hunger activates brain circuits involved in homeostatic appetite while, on the other hand complete satiety will shut down any food craving. For that purpose, participants will be asked to time their meals in order to start the session 1-2 hours after a medium-large meal. The investigators will document in detail the last meal (timing, content, estimated caloric value) and explore correlative parameters in the hormonal profile. Participants will be asked to rate their hunger, satiety, fullness and prospective eating in visual analogue scales: graphic questioners that are commonly used and well validated in eating behavior research field.

fMRI data acquisition: Functional scanning will be performed using a 3 Tesla whole body MRI system (GE EXITE HDxt, most updated version 14 M5) equipped with 8-channel head coil. Each scan will be acquired using a standard gradient echo planar imaging (EPI) sequence. After each volume is acquired, it will be automatically transferred in DICOM format from the MRI scanner computer to a separate computer for in-scan processing.

fMRI data processing: Online RT-fMRI processing will be made possible via a fast connection between the MRI scanner and the analysis/display computer. Turbo-Brain Voyager (TBV) 2.0 software (Brain Innovation, Maastricht, the Netherlands) will be used to perform real-time in-scan processing. TBV is capable of incrementally computing statistical maps based on General Linear Model (GLM) and event-related averages.

Off-line fMRI analysis:

Off-line analysis will be conducted to all data collected. Off-line analysis will be performed using Statistical Parametric Mapping software 8 (SPM8. The Welcome Department of Cognitive Neurology, London, UK). While MarsBar toolbox (the Marseille region of interest toolbox for SPM) will be used for ROI analysis.

Neurofeedback sessions Participants will undergo 10 H.E.G. sessions, twice weekly, over 5 weeks of intervention. They will be instructed to come to sessions in a "half-satiated" condition in order to focus on hedonic/emotional brain circuits involved in eating behavior rather than physiological circuits, based on the "real", physiological hunger. Participants will be given introspective tasks of mindfulness, increased sense of self-control and reduced food craving and will be instructed to attempts augmentation for visual feedback. These tasks correlate with modulation of our ROIs: Increase self-control - is adjusted to increase activity in the superior orbitofrontal cortex (sOFC) whereas suppressing food craving is adjusted to modification of neural activity in the anterior cingulated cortex (ACC) bilaterally. Successive feedback regarding changes in activity in this region will be given analogically with a thermometer with bars above baseline level of activation colored in red while those below baseline colored blue. Thermometer bars are constantly updated with a minimal inherent delay.

02

Conditions studied

  • Obesity

Keywords

  • functional MRI
  • appetite
  • neurofeedback
03

In context

Lead sponsor

Sheba Medical Center is the lead sponsor of 660 studies on the registry; 63 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

Right handed BMI in the range of 28-35kg/m2

Exclusion criteria

Exclusion Criteria:

  • Current or past history of any major psychiatric disorder
  • Major medical or neurological disorders
  • Exposure to drugs likely to influence cerebral blood flow or neurological function within 3 weeks
  • History of drug or alcohol abuse
  • General MRI exclusion criteria
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (estimated)

Study arms

  • Experimental
    single arm pilot feasibility study

    Hematoencephalography bio/neurofeedback for Brain neural activity modulation. H.E.G. (hematoencephalography) based neurofeedback program. No drug use.

    Device: H.E.G. (hematoencephalography) based neurofeedback

Interventions

  • DeviceH.E.G. (hematoencephalography) based neurofeedback

    H.E.G. is a relatively new neurofeedback technique which, similar to fMRI is based on differential oxygenated blood supply according to regional brain activity.

    Also known as: ProComp2 - 2 Channel Biofeedback & Neurofeedback System w/ BioGraph Infiniti Software - T7400M

06

What researchers measure

Primary outcomes

  1. Increase brain activity in frontal brain areas

    Time frame: 7 weeks

Secondary outcomes

  1. Increased activation of superior frontal brain regions and middle temporal regions in response to food stimuli, in the second fMRI session, perforemed after the neurofeedback sessions, compared to baseline session

    Activation of superior frontal brain regions and middle temporal regions in response to food stimuli, known to correlate with inhibition, self control and executive functions.

    Time frame: 7 weeks

  2. Behavioural measures

    Increased scores of self control and inhibition and decreased scores of binge eating and emotional eating on questionnaires.

    Time frame: 12 months

  3. Anthropometric measures

    weight loss according to follow-up 6 and 12 months after intervention.

    Time frame: 12 months

  4. Number of participants with adverse events

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Percik R, Cina J, Even B, Gitler A, Geva D, Seluk L, Livny A. A pilot study of a novel therapeutic approach to obesity: CNS modification by N.I.R. H.E.G. neurofeedback. Clin Nutr. 2019 Feb;38(1):258-263. doi: 10.1016/j.clnu.2018.01.023. Epub 2018 Feb 15. PubMed 29428788 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02480179
Lead sponsor
Sheba Medical Center
Responsible party
Dr. Ruth Perchik (Dr., Sheba Medical Center) — Principal investigator
First posted
Jun 24, 2015
Start date
Jun 2015
Primary completion
Oct 2015 (estimated)
Completion
Apr 2016 (estimated)
Last update
Jun 24, 2015

Study contacts

Ruth Percik, MD
Contact
ruthpercik@gmail.com
972-3-5302021
Jenny Cina, Ph.D
Contact
jennycinaphd@gmail.com
972-3-5308493
Ruth Percik, MD
principal investigator · Sheba Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion